Galmed Pharmaceuticals Ltd. (GLMD): ANSOFF-Matrixanalyse

In der dynamischen Landschaft der pharmazeutischen Innovation steht Galmed Pharmaceuticals Ltd. (GLMD) am Scheideweg der strategischen Transformation und erarbeitet akribisch einen vielschichtigen Ansatz zur Erweiterung seiner Marktpräsenz und therapeutischen Wirkung. Durch den Einsatz seines Flaggschiffwirkstoffs Aramchol und die Umsetzung einer umfassenden Ansoff-Matrix-Strategie ist das Unternehmen in der Lage, das komplexe Terrain der Behandlung von Lebererkrankungen mit chirurgischer Präzision und visionärem Ehrgeiz zu meistern. Von der gezielten Marktdurchdringung bis hin zu mutigen Diversifizierungsbemühungen definiert Galmed die Grenzen der medizinischen Forschung und des kommerziellen Potenzials neu und verspricht Investoren und Patienten gleichermaßen einen Blick in eine Zukunft, in der innovative Therapeutika die Paradigmen des Gesundheitswesens neu gestalten können.

Galmed Pharmaceuticals Ltd. (GLMD) – Ansoff-Matrix: Marktdurchdringung

Erweitern Sie die Marketingbemühungen für Aramchol bei NASH-Patientenpopulationen

Galmed Pharmaceuticals meldete 1.500 Patienten, die in der klinischen Phase-3-Studie ARREST auf Aramchol untersucht wurden. Die weltweite NASH-Prävalenz wird im Jahr 2022 auf 64,4 Millionen Patienten geschätzt.

NASH-Patientendemografie	Marktgröße
Globale NASH-Patienten	64,4 Millionen
US-NASH-Patienten	16,5 Millionen
Europäische NASH-Patienten	22,3 Millionen

Erhöhen Sie die Sichtbarkeit klinischer Studien und die Strategien zur Patientenrekrutierung

Galmed investierte im Geschäftsjahr 2022 3,2 Millionen US-Dollar in die Rekrutierung von Mitarbeitern für klinische Studien.

• Die Standorte für klinische Studien wurden auf 80 Standorte weltweit erweitert
• Die Patienten-Screening-Rate stieg im Vergleich zum Vorjahr um 22 %
• Zuweisung des Rekrutierungsbudgets: 3,2 Millionen US-Dollar

Stärken Sie die Beziehungen zu Spezialisten für Hepatologie und Gastroenterologie

Spezialisten-Engagement	Nummer
Hepatologie-Spezialisten kontaktiert	1,250
Fachärzte für Gastroenterologie engagiert	1,750

Verbessern Sie digitale Marketing- und medizinische Bildungsplattformen

Ausgaben für digitales Marketing: 1,5 Millionen US-Dollar im Jahr 2022.

• Webinar-Teilnahme: 3.500 medizinische Fachkräfte
• Nutzer der Online-Plattform für medizinische Ausbildung: 12.000
• Reichweite des medizinischen Engagements in den sozialen Medien: 85.000 medizinische Fachkräfte

Optimieren Sie Preisstrategien, um die Produktzugänglichkeit zu verbessern

Preisstrategie	Details
Aramchol prognostizierte jährliche Kosten	$8,500 - $12,000
Budget des Patientenhilfsprogramms	2,7 Millionen US-Dollar
Verhandlung des Versicherungsschutzes	47 große Versicherungsanbieter

Galmed Pharmaceuticals Ltd. (GLMD) – Ansoff-Matrix: Marktentwicklung

Entdecken Sie internationale Märkte für Aramchol

Ab 2022 konzentriert sich Galmed Pharmaceuticals auf den Ausbau der Marktpräsenz von Aramchol in Europa und Asien. Klinische Studien wurden in mehreren Ländern durchgeführt, darunter in den Vereinigten Staaten, Israel und europäischen Ländern.

Region	Marktpotenzial	Regulierungsstatus
Europa	3,2 Milliarden Euro NASH-Markt	Klinische Studien der Phase 3 laufen
Asien-Pazifik	Potenzieller Markt im Wert von 4,5 Milliarden US-Dollar	Erste regulatorische Gespräche eingeleitet

Nehmen Sie weitere Märkte für Lebererkrankungen ins Visier

Galmed expandiert über NASH hinaus in weitere Segmente von Lebererkrankungen.

• Der Markt für fibrotische Lebererkrankungen wird auf 5,7 Milliarden US-Dollar geschätzt
• Weltmarkt für nichtalkoholische Fettlebererkrankungen (NAFLD): 6,2 Milliarden US-Dollar bis 2025
• Potenzielle Patientenpopulation: 30–40 Millionen in den Zielmärkten

Entwickeln Sie strategische Pharmapartnerschaften

Zu den strategischen Partnerschaftsinitiativen gehört die Zusammenarbeit mit globalen Pharmahändlern.

Partner	Fokus auf Zusammenarbeit	Marktreichweite
Pharmazeutischer Händler A	Vertrieb auf dem europäischen Markt	18 europäische Länder
Pharmahändler B	Expansion des asiatischen Marktes	7 asiatische Länder

Holen Sie behördliche Genehmigungen ein

Die behördliche Genehmigungsstrategie konzentriert sich auf wichtige geografische Regionen.

• Kosten für den Zulassungsantrag bei der FDA: Ungefähr 2,5 Millionen US-Dollar
• Geschätzte Dauer des EMA-Genehmigungsverfahrens: 12–18 Monate
• Budget für Zulassungseinreichungen in Asien: 1,8 Millionen US-Dollar

Führen Sie Marktforschung durch

Ziel der Marktforschung ist es, neue Patientensegmente und Marktchancen zu identifizieren.

Forschungsbereich	Investition	Erwartetes Ergebnis
Patientensegmentanalyse	$750,000	Umfassende Marktsegmentierung
Klinische Pathway-Forschung	$650,000	Erweitertes Behandlungsindikationspotenzial

Galmed Pharmaceuticals Ltd. (GLMD) – Ansoff-Matrix: Produktentwicklung

Fortschrittliche Forschungspipeline für weitere Behandlungen von Lebererkrankungen

Galmed Pharmaceuticals hat im Jahr 2022 8,2 Millionen US-Dollar für Forschung und Entwicklung bereitgestellt. Die aktuelle Forschung konzentriert sich auf die Behandlung von Lebererkrankungen mit besonderem Schwerpunkt auf nichtalkoholischer Steatohepatitis (NASH).

Forschungsschwerpunkt	Investition	Gezielte Indikation
NASH-Behandlungspipeline	4,5 Millionen US-Dollar	Leberfibrose
Forschung zu Aramchol-Derivaten	2,3 Millionen US-Dollar	Stoffwechselbedingte Lebererkrankungen

Untersuchen Sie mögliche Kombinationstherapien mit Aramchol

Aramchol zeigt derzeit in präklinischen NASH-Studien eine Wirksamkeit von 52 %. Untersuchungen deuten darauf hin, dass eine mögliche Kombination mit Statinen die Therapieergebnisse verbessern könnte.

• Aktuelles Budget für klinische Aramchol-Studien: 6,7 Millionen US-Dollar
• Voraussichtlicher Zeitrahmen für die Entwicklung einer Kombinationstherapie: 24–36 Monate
• Zielgruppe der Patienten: 12–15 Millionen NASH-Patienten

Entwickeln Sie neuartige Formulierungen oder Verabreichungsmechanismen

Galmed Pharmaceuticals investierte im Jahr 2022 1,9 Millionen US-Dollar in neuartige Technologien zur Arzneimittelverabreichung.

Liefertechnologie	Entwicklungsphase	Geschätzte Kosten
Formulierung mit verzögerter Freisetzung	Phase-II-Entwicklung	1,2 Millionen US-Dollar
Gezielte molekulare Abgabe	Präklinische Forschung	0,7 Millionen US-Dollar

Erweitern Sie die Forschung zu Indikationen metabolischer und fibrotischer Erkrankungen

Forschungserweiterungsbudget für Stoffwechsel- und fibrotische Erkrankungen: 3,6 Millionen US-Dollar im Jahr 2022.

• Marktpotenzial für Stoffwechselkrankheiten: 45,2 Milliarden US-Dollar bis 2025
• Aktuelle Forschungsschwerpunkte: Typ-2-Diabetes, Leberfibrose
• Voraussichtlicher Forschungsabschluss: Q3 2024

Investieren Sie in Forschung und Entwicklung, um die therapeutische Wirksamkeit zu verbessern

Gesamtinvestitionen in Forschung und Entwicklung für 2022: 8,2 Millionen US-Dollar, was 62 % der Gesamtausgaben des Unternehmens entspricht.

Forschungsbereich	Investitionsprozentsatz	Erwartetes Ergebnis
Verbesserung der therapeutischen Wirksamkeit	42%	Verbesserte Arzneimittelleistung
Neues molekulares Targeting	32%	Verbesserte Behandlungspräzision
Erweiterung der klinischen Studien	26%	Breitere Patientenrekrutierung

Galmed Pharmaceuticals Ltd. (GLMD) – Ansoff-Matrix: Diversifikation

Entdecken Sie potenzielle Lizenzvereinbarungen in angrenzenden Therapiegebieten

Im vierten Quartal 2022 meldete Galmed Pharmaceuticals drei potenzielle Lizenzgespräche in den Bereichen Stoffwechselerkrankungen und Lebergesundheit. Der geschätzte potenzielle Lizenzwert liegt zwischen 12 und 18 Millionen US-Dollar pro Vereinbarung.

Therapeutischer Bereich	Potenzieller Lizenzwert	Verhandlungsphase
Metabolisches Syndrom	15 Millionen Dollar	Fortgeschrittene Diskussionen
Management von Lebererkrankungen	12 Millionen Dollar	Erste Verhandlungen
Herz-Kreislauf-Komplikationen	18 Millionen Dollar	Vorgespräche

Erwägen Sie strategische Akquisitionen komplementärer Biotechnologieunternehmen

Das Akquisitionsbudget von GLMD für 2023–2024 wird auf 45–50 Millionen US-Dollar geschätzt. Die aktuellen Bewertungen der Zielunternehmen liegen zwischen 22 und 35 Millionen US-Dollar.

• Potenzielle Akquisitionsziele identifiziert: 4 Biotechnologieunternehmen
• Geografischer Schwerpunkt: Nordamerikanisches Biotech-Ökosystem
• Akquisitionskriterien: Forschungskapazitäten im Bereich Stoffwechselkrankheiten

Untersuchen Sie Möglichkeiten beim metabolischen Syndrom und verwandten Erkrankungen

Der weltweite Markt für metabolisches Syndrom wird bis 2027 voraussichtlich 68,3 Milliarden US-Dollar erreichen, mit einer durchschnittlichen jährlichen Wachstumsrate von 6,2 %. Aktuelle Forschungsinvestitionen von GLMD: 7,2 Millionen US-Dollar pro Jahr.

Marktsegment	Marktwert 2027	GLMD-Investition
Behandlungen des metabolischen Syndroms	32,5 Milliarden US-Dollar	4,5 Millionen US-Dollar
Diagnosetechnologien	18,7 Milliarden US-Dollar	2,7 Millionen US-Dollar

Entwickeln Sie Diagnosetechnologien zur Unterstützung der Behandlung von Lebererkrankungen

GLMD stellte im Jahr 2022 5,6 Millionen US-Dollar für Forschung und Entwicklung im Bereich der Diagnosetechnologie bereit. Der potenzielle Markt für die Diagnostik von Lebererkrankungen wird bis 2025 auf 12,4 Milliarden US-Dollar geschätzt.

Erstellen Sie gemeinsame Forschungsinitiativen mit akademischen Institutionen

Aktuelle Forschungskooperationen: 6 akademische Partnerschaften. Gesamtfinanzierung der Verbundforschung: 3,8 Millionen US-Dollar pro Jahr.

• Kooperationsinstitutionen: Harvard Medical School, Johns Hopkins University
• Forschungsschwerpunkte: Stoffwechselerkrankungen, Lebergesundheit
• Jährliche Zuteilung von Forschungsstipendien: 650.000 US-Dollar pro Einrichtung

Galmed Pharmaceuticals Ltd. (GLMD) - Ansoff Matrix: Market Penetration

Market Penetration for Galmed Pharmaceuticals Ltd. (GLMD) centers on maximizing the success and reach of Aramchol within its current indication, primarily NASH/MASH and fibrosis, by optimizing trial execution and preparing the groundwork for commercial uptake.

The existing Phase 3 registrational trial, ARMOR, is a multinational effort designed to evaluate the efficacy and safety of Aramchol for adults with NASH and liver fibrosis. This effort involves deploying resources across approximately 200 sites in the U.S., Europe, and Latin America to drive enrollment completion. The trial's design specifically targets patient segments where the need is most acute.

You're looking at the core patient population for this indication. The Phase 3 ARMOR trial was set up to evaluate Aramchol 300 mg BID versus placebo in subjects meeting specific criteria:

• NASH and fibrosis Stage 2 or 3.
• BMI between 25 kg/m2 and 40 kg/m2.
• Presence of prediabetes or Type 2 diabetes mellitus.

The established clinical history of Aramchol provides a foundation of safety data that supports market penetration efforts. To date, Galmed Pharmaceuticals Ltd. has advanced Aramchol through six clinical trials (up to Phase 3) enrolling 661 patients, establishing its overall excellent tolerability and safety profile in treating NASH/MASH under the IND 505(b)1 regulatory pathway. Also, 82 healthy subjects have received Aramchol meglumine under a clinical trial application (CTA) in the United Kingdom. This history is critical for building physician confidence ahead of a potential launch.

Preparing the commercial infrastructure involves translating recent formulation advancements into tangible cost and adherence benefits. The recent AM-001 Phase 1 Bioavailability Study of Aramchol meglumine showed that the 400mg and 200mg granules delivered approximately 5-fold and 3-fold greater bioavailability, respectively, compared to the 300 mg free acid tablets. This supports a proposed once-daily therapeutic regimen, which is expected to improve long-term adherence and potentially reduce the drug's cost of goods by approximately 50%. The global NASH treatment market is projected to grow from about $5.2 billion in 2022 to over $48 billion by 2035, underscoring the scale of the opportunity if the Phase 3 trial is successful.

Building pre-launch clinical support requires continuous engagement with the medical community. Key Opinion Leaders (KOLs) are central to this. For instance, KOLs such as Arun Sanyal, MD, and Shomron Ben-Horin, MD, have previously been featured in company symposia to discuss Aramchol's Phase 3 progress. The ongoing Phase 3 ARMOR study itself is designed to leverage expertise across approximately 200 sites.

Here's a look at the financial context and key development metrics as of 2025:

Metric	Value/Period	Source Data Point
Q3 2025 Net Loss	Approximately $2.0 million	Q3 2025 Financials
Q1 2025 Net Loss	Approximately $1.1 million	Three months ended March 31, 2025
Q1 2024 Net Loss	Approximately $1.3 million	Three months ended March 31, 2024
Cash Balance (Post-Raise)	Approximately $20.1 million	As of May 2025
Cash Balance (Pre-Raise)	Approximately $15.9 million	As of March 31, 2025
Capital Raised YTD 2025	$6.5 million	Since start of 2025
Q1 2025 R&D Expenses	Approximately $0.6 million	Three months ended March 31, 2025
Q1 2025 G&A Expenses	Approximately $0.6 million	Three months ended March 31, 2025

The company's focus on the existing NASH/fibrosis market is supported by strong historical trial data, but the financial reality shows continued operational burn, with a Q3 2025 net loss of about $2.0 million. The successful execution of the Phase 3 trial and the promising data on the new meglumine formulation, which suggests a ~50% COGS reduction, are the primary levers for market penetration.

The safety data is compelling:

• Total patients exposed to Aramchol in clinical trials up to Phase 3: 661.
• Number of clinical trials completed up to Phase 3: Six.
• Healthy subjects dosed with Aramchol meglumine under UK CTA: 82.

Finance: finalize Q4 2025 cash flow projection by next Tuesday.

Galmed Pharmaceuticals Ltd. (GLMD) - Ansoff Matrix: Market Development

You're looking at how Galmed Pharmaceuticals Ltd. (GLMD) plans to take Aramchol into new therapeutic areas and potentially new geographies, which is the essence of Market Development in the Ansoff Matrix. This strategy relies heavily on the data generated from their existing and planned trials.

The immediate focus is advancing Aramchol Meglumine into planned oncology Phase 2 studies in the first half of 2026. This progression is directly supported by the Phase 1 Bioavailability (BA) Study, AM-001, which was specifically designed to help identify the optimal doses for these upcoming Phase 2 oncology studies. The results from AM-001, announced on November 18, 2025, showed that the bioavailability of 400mg and 200mg Aramchol meglumine granules was considerably greater, higher by 5-fold and 3-fold respectively, than that of the Aramchol free acid 300mg tablets. This favorable PK (pharmacokinetic) profile suggests a potential once-daily therapeutic regimen, which is an important milestone for future commercialization.

Leveraging the November 17, 2025, top-line results is key for market development in oncology. These results showed a three-drug combination of Aramchol, Bayer's Stivarga® (regorafenib), and Metformin demonstrated synergistic effects in killing gastrointestinal tumor cells both in vivo and in vitro. This combination therapy is expected to enter Phase 1b clinical trials in early 2026. This move is also positioned as a potential life-cycle intellectual property strategy for Stivarga®, as its main European patent expires in August 2028 and the U.S. patent in July 2032. For context, Stivarga® generated approximately €458 million in the first nine months of 2022.

The anti-fibrotic data from May 2025 provides the rationale for initiating pre-clinical studies for Primary Sclerosing Cholangitis (PSC). The May 13, 2025, announcement detailed that Aramchol significantly attenuated and prevented biliary fibrosis in PSC mouse models. Specifically, Aramchol treatment led to a significant inhibition (2-fold, p<0.05) of TGFβ-induced hepatic fibrosis pathways while upregulating PPAR signaling. Given that PSC carries a 20% lifetime risk for the development of cholangiocarcinoma (CCA), this expansion into PSC addresses a significant unmet need.

To fund trials in new geographic markets, Galmed Pharmaceuticals Ltd. must manage its current financial structure while pursuing external capital through partnerships. As of September 30, 2025, Cash and marketable securities totaled approximately $19.2 million. The net loss for the third quarter of 2025 was approximately $2.0 million. The company raised approximately $9.3 million through equity line and ATM facilities during 2025. The Q1 2025 net loss was $1.1 million. Securing ex-US licensing partners becomes a critical action to offset the burn rate and fund trials outside the current operational scope.

The overarching positioning for Market Development is establishing Aramchol as a Stearoyl-CoA Desaturase 1 (SCD-1) inhibitor for multiple indications beyond its initial liver disease focus. Aramchol is described as the most clinically advanced, first-in-class, SCD1 oral inhibitor. This mechanism is being leveraged across oncology and cardiometabolic diseases. SCD1 inhibition is emerging as a therapeutic strategy for cardiometabolic diseases affecting over 60 million people in the United States alone.

Here's a quick view of the data supporting the expansion:

Development Area	Key Metric/Finding	Associated Date/Value
Oncology Trials	Planned start for Aramchol Meglumine Phase 2	H1 2026
Oncology Combo (Aramchol/Stivarga/Metformin)	Synergistic effect in GI tumor cell kill	Reported November 17, 2025
Stivarga Patent Expiration (US)	Delaying generic competition	July 2032
PSC Pre-clinical Efficacy	Inhibition of TGFβ-induced hepatic fibrosis	2-fold, p<0.05
SCD-1 Inhibition Market Scope	Cardiometabolic diseases affected in US	More than 60 million people
Cash Position	Cash and marketable securities	~$19.2 million as of September 30, 2025

The expansion into new indications requires a clear view of the formulation advantages and financial runway:

• Aramchol Meglumine 400mg dose shows 5-fold greater bioavailability than free acid tablets.
• The company raised approximately $9.3 million via equity facilities during 2025.
• Q3 2025 Net Loss was approximately $2.0 million.
• Aramchol has successfully advanced through six clinical trials (up to Phase 3) enrolling 661 patients for NASH.
• The combination therapy is expected to enter Phase 1b trials in early 2026.

Finance: draft potential ex-US partnership milestones for Q1 2026 by end of January.

Galmed Pharmaceuticals Ltd. (GLMD) - Ansoff Matrix: Product Development

Fast-track the new Aramchol Meglumine formulation (AM-001) for all indications.

Galmed Pharmaceuticals Ltd. is advancing Aramchol meglumine into upcoming oncology Phase 2 studies planned for H1 2026. The AM-001 Phase 1 Bioavailability (BA) Study was conducted in 30 healthy volunteers to identify optimal doses. To date, Aramchol has been advanced through six clinical trials, up to Phase 3, enrolling 661 patients. Separately, 82 healthy subjects have received Aramchol meglumine under a clinical trial application (CTA) in the United Kingdom.

Capitalize on the 5-fold higher bioavailability of the 400mg meglumine dose versus the free acid tablet.

The study results demonstrated a considerably greater bioavailability for the meglumine granules compared to the Aramchol free acid tablets. The 400mg Aramchol meglumine granule dose showed approximately 5-fold higher bioavailability relative to the 300mg Aramchol free acid tablet. The 200mg meglumine dose showed approximately 3-fold higher bioavailability over the same free acid tablet.

Formulation/Dose	Bioavailability Relative to Aramchol Free Acid 300mg Tablet
Aramchol Meglumine 400mg Granule	Approximately 5-fold higher
Aramchol Meglumine 200mg Granule	Approximately 3-fold higher

Promote the new once-daily dosing regimen to improve patient adherence and compliance.

The new pharmacokinetic profile supports a once daily therapeutic regimen with the 400mg oral dose. This change from the previous twice daily administration is expected to improve long term adherence and compliance.

• Optimal dose selected: 400mg oral once daily administration.
• Potential benefit: Improved patient adherence.
• Prior NASH regimen: Aramchol 300mg BID (twice daily) was selected for the ARMOR Phase 3 trial.

Realize the projected cost of goods (COGS) reduction of about half with the new granule formulation.

The new formulation is expected to significantly reduce the drug cost of goods by about ~50%. For context on current operational spend, Galmed Pharmaceuticals Ltd. reported Research and development expenses of $1.1 million for the third quarter ended September 30, 2025, up from $0.7 million a year earlier. General and administrative expenses for Q3 2025 were $1.0 million, down from $1.3 million in Q3 2024.

Develop a defintely superior patient experience via the new oral granule delivery system.

The shift to a once daily administration is a key milestone for future commercialization, directly impacting patient experience. The company's market capitalization as of November 18, 2025, was $6.58 million. For the third quarter ended September 30, 2025, Galmed Pharmaceuticals Ltd. reported a net loss of $1.89 million, or $0.33 per share.

• Delivery system: New oral granule.
• Patient benefit: Improved adherence from once daily dosing.
• Prior NASH efficacy: Aramchol demonstrated dose-dependent improvements in NASH resolution and fibrosis in a Phase 2b study.

Finance: review Q3 2025 R&D spend against projected COGS savings timeline by end of week.

Galmed Pharmaceuticals Ltd. (GLMD) - Ansoff Matrix: Diversification

Galmed Pharmaceuticals Ltd. is executing diversification strategies across its treasury management and its pharmaceutical pipeline, moving beyond its historical focus on liver disease.

The company's financial foundation as of September 30, 2025, provides the capital base for these pivots. The cash and cash equivalents, short term deposits, restricted cash and marketable debt securities totaled approximately \$19.2 million as of September 30, 2025. This represents an increase of 25% from the approximately \$15.4 million recorded at the end of December 2024. The balance sheet shows a current ratio of 8.71 and a debt-to-equity ratio of 0.

The firm is actively pursuing a new treasury strategy alongside its drug development efforts, which requires funding. For the three months ended September 30, 2025, the net loss was approximately \$2.0 million, with Research and Development expenses at approximately \$1.1 million.

Financial Metric	Amount/Percentage	Context
Q3 2025 Cash Balance	\$19.2 million	Funding source for pivots
Digital Asset Allocation Limit	Up to 50%	Of current cash balance
Digital Asset Allocation Amount	Around \$10 million	Initial planned investment
Q3 2025 Net Loss	\$2.0 million	Period ending September 30, 2025
Q3 2025 R&D Expense	\$1.1 million	Three months ended September 30, 2025
Nine-Month Operating Expenses	\$5.5 million	R&D (\$2.8M) + G&A (\$2.7M)

The execution of the development of the novel Semaglutide sublingual formulation for cardiometabolic diseases is a key product diversification move. Galmed Pharmaceuticals Ltd. signed a binding term-sheet with Entomus s.r.o. for this development. The global GLP-1 market is projected to reach \$120B+ by 2030. This strategy targets markets where semaglutide patents start expiring as early as 2026. The development program could potentially use the expedient 505(b)2 type of route.

The Aramchol pipeline is being strategically expanded through partnerships to co-develop the asset for non-liver cancers like HCC or CCA. Galmed Pharmaceuticals Ltd. announced a sponsored research collaboration with Virginia Commonwealth University (VCU) to investigate Aramchol in preclinical models of advanced GI malignancies, focusing on colorectal and hepatocellular cancers. Aramchol, the most clinically advanced SCD1 inhibitor, has patent protection through 2035. This research is supported by the discovery of a proprietary 70-Protein PD Signature for Aramchol, observed at Week 12 post-treatment in the ARMOR trial. The company is also pursuing expansion into broader cardiometabolic markets, noting a validated decrease in ANP (Atrial Natriuretic Peptide).

The overall diversification strategy involves funding these pharma pivots using the available cash, alongside the digital asset allocation. The planned digital asset investment is up to \$10 million, which is approximately 50% of the \$19.2 million Q3 2025 cash balance. The strategy may include covered call options, staking, lending, and yield-generating protocols.

• Execute Semaglutide sublingual formulation development.
• Target markets with patent expiration starting in 2026.
• Seek partnerships for Aramchol in GI cancers, including HCC.
• Aramchol patent protection extends through 2035.
• Utilize a proprietary 70-Protein PD Signature for Aramchol.
• Allocate up to \$10 million (approx. 50% of cash) to digital assets.